Less than a year after Affymetrix bought eBioscience, the array vendor is finding ways to combine its background in microarray and branched-DNA genotyping and expression with eBio's flow cytometry reagents and multiplex immunoassay portfolios.

As an example of this ongoing integration process, eBioscience, now one of four business units under the Affy umbrella, is moving its menu of FlowCytomix multi-analyte, bead-based immunoassays to the Luminex xMAP platform, said Tony Ward, eBio's vice president of commercial affairs.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.